These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15479935)

  • 1. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine.
    Wise RP; Iskander J; Pratt RD; Campbell S; Ball R; Pless RP; Braun MM
    JAMA; 2004 Oct; 292(14):1702-10. PubMed ID: 15479935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
    Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
    Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.
    Tseng HF; Sy LS; Liu IL; Qian L; Marcy SM; Weintraub E; Yih K; Baxter R; Glanz JM; Donahue J; Naleway A; Nordin J; Jacobsen SJ
    Vaccine; 2013 May; 31(22):2578-83. PubMed ID: 23579258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.
    Myers TR; McNeil MM; Ng CS; Li R; Lewis PW; Cano MV
    Vaccine; 2017 Mar; 35(14):1758-1763. PubMed ID: 28262331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
    Haber P; Arana J; Pilishvili T; Lewis P; Moro PL; Cano M
    Vaccine; 2016 Dec; 34(50):6330-6334. PubMed ID: 27836437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postlicensure safety surveillance for varicella vaccine.
    Wise RP; Salive ME; Braun MM; Mootrey GT; Seward JF; Rider LG; Krause PR
    JAMA; 2000 Sep; 284(10):1271-9. PubMed ID: 10979114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.
    Chang S; O'Connor PM; Slade BA; Woo EJ
    Vaccine; 2013 Feb; 31(10):1447-52. PubMed ID: 23142308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
    Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
    Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual report: Surveillance of adverse events following immunisation in Australia, 2011.
    Mahajan D; Cook J; Dey A; Macartney K; Menzies RI
    Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Neuzil KM; Whitney CG; Starkovich P; Dunstan M; Yu O; Nelson JC; Feikin DR; Shay DK; Baggs J; Carste B; Nahm MH; Carlone G
    Vaccine; 2005 May; 23(28):3697-703. PubMed ID: 15882530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.
    Black SB; Shinefield HR; Ling S; Hansen J; Fireman B; Spring D; Noyes J; Lewis E; Ray P; Lee J; Hackell J
    Pediatr Infect Dis J; 2002 Sep; 21(9):810-5. PubMed ID: 12352800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California.
    Black S; Shinefield H
    Eur J Pediatr; 2002 Dec; 161 Suppl 2():S127-31. PubMed ID: 12494258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.